ACADIA Pharmaceuticals Inc at JPMorgan Healthcare Conference Transcript
Welcome, everyone, to the 42nd Annual JPMorgan Healthcare Conference. My name is Tessa Romero. I'm one of the senior biotech analysts here at JPMorgan. Our next presenting company is ACADIA Pharmaceuticals. And speaking on behalf of the company, we're pleased to have CEO, Steve Davis. Steve?
Great. Thanks much, Tess, and thanks to each of you for coming out today. I need to start with the obligatory disclaimer regarding forward-looking statements. The business of drug discovery development and commercialization has a lot of inherent risks. Please see our most recent SEC filings for a description of those risks as they relate to our business.
Our business rests on 3 pillars. We have 2 successful commercial franchises driving record revenues, 3 late-stage assets with a strong early-stage pipeline fueling future growth. And we're a cash flow positive company, which further enables us to pursue that
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |